How Will The Supreme Court Choreograph The Biosimilar Patent Dance?

by Foley & Lardner LLP
Contact

On April 26, 2017, the Supreme Court heard oral arguments in Amgen v. Sandoz, where the parties have asked the Court to interpret two of the biosimilar patent dance provisions of the Biologics Price Competition and Innovation Act (BPCIA). While it is never wise to predict how the Justices will rule based on the questions and comments at oral hearing, I would not be surprised if they uphold the Federal Circuit’s interpretation of this complicated statute.

The Questions Presented

As summarized in this article, there are two issues of statutory construction before the Court:

  1. Can the notice of commercial marketing required by 42 U.S.C. § 262(l)(8)(A) be given before the FDA has approved the biosimilar product? (The Federal Circuit said no; Sandoz urges yes)
  2. Do biosimilar applicants have to share their biosimilar application and other information in accordance with 42 U.S.C. § 262(l)(2)(A)? (The Federal Circuit said no; Amgen urges yes)

Although the Solicitor General of the United States filed an amicus brief that sided with Sandoz on both issues, the Justices seemed inclined to affirm the Federal Circuit on both issues.

What Would You “Notice” Prior To Approval?

The Justices who commented on this issue seemed to agree with the Federal Circuit that the notice of commercial marketing required by 42 U.S.C. § 262(l)(8)(A) cannot be given until the FDA has approved the biosimilar product—otherwise what would you be giving notice of?

Justice Breyer: What does this notice say? And what it says is that you have to provide … notice of … first commercial marketing of the biological product licensed. …. Now, how could you do that if you don’t know what the product licensed is?

Once this notice has been given, the Reference Product Sponsor has an opportunity to assert any remaining patents. Thus, the Justices asked how the Reference Product Sponsor would know which patents could be asserted if the biosimilar product had not yet been approved. Sandoz’s attorney argued that the very nature of a biosimilar product would provide such information:

Ms. Maynard: By definition, a biosimilar is highly similar to the reference-product sponsor’s product. So a reference-product sponsor would have good-faith basis in that case to bring suit on any patent that covers its own product, or any patent that covers a use of its own product.

Chief Justice Roberts wasn’t entirely convinced:

CHIEF JUSTICE ROBERTS: But it doesn’t know the specifics of the biosimilar. I mean, by definition, the biosimilar is similar; it’s not identical. And whether or not it infringes might have something to do with the ways in which it is different.

On the other hand, Justice Kagan pointed out that the “patent dance” litigation is based on the biosimilar application, and so would suffer from the same uncertainty vis-a-vis any changes embodied in the approved product:

JUSTICE KAGAN: But isn’t that true of a lot of what this Act contemplates? I mean, all the round 1 litigation can occur before the approval is given.

Should Reference Product Sponsors Have 12.5 Years Exclusivity?

None of the Justices seemed comfortable with the consequence of requiring approval prior to notice, i.e., effectively providing the original biologic product with an additional 180 days of market exclusivity. There was some discussion of whether the FDA might be able to approve or signal approval of a biosimilar product before the 12 year period had run (but only make the approval effective at 12 years), but as I wrote in this article it is not clear that the FDA would or could do so.

What About The Biosimilar Patent Dance?

Although Amgen had framed the “patent dance” issue as whether “shall” means “shall,” the Justices focused on the statutory consequences for violating the “shall” requirement. On this issue, they seemed to agree that the only remedy available to a Reference Product Sponsor if the biosimilar application does not provide the information required by § 262(l)(2)(A) is to bring a declaratory judgment action under § 262(l)(9)(C):

GORSUCH: Mr. Waxman, let’s say -let’s say I spot you that, okay, that (2)(A) “shall” means shall. …. And how can we possibly decide what (2)(A) means without taking a peek at (9)(C) as to what remedies are permitted? …. You can’t –it’s hard to divorce a right from its remedy, isn’t it, and to understand the contours of the right. And if (2)(A) gives you a certain right to information, we usually understand the right in the context of the remedy provided. …. And here the remedy is (9)(C).

Justice Sotomayor read the statutory scheme differently, as presenting two options for resolving patent disputes:

JUSTICE SOTOMAYOR: “Shall” is if you want to invoke this Federal process [the patent dance], this is what you have to do. …. So if you don’t invoke the Federal process, what remains? That’s not a remedy. That’s a different Federal process, the declaratory-judgment process. That’s what (C) says.

Were Amgen’s State Law Claims Preempted?

Although neither party had briefed the issue, the Justices asked both parties about preemption of the state law claims that Amgen had asserted against Sandoz. Arguing for the United States, the Assistant to the Solicitor General came the closest to taking a position on this issue:

MR. YANG: I think there are strong arguments that this would be preempted. This is a highly detailed scheme. And if States were to start to interject different means of enforcing it on a State-by-State basis, that might wreak some havoc, but we’ve not taken a position on that.

Why Hasn’t An Agency Interpreted These Provisions

One interesting theme in the Justices’ questions was their wondering why an agency (the FDA or PTO) had not weighed in on these issues in the first instance.

JUSTICE BREYER: Now, we are being asked to interpret very technical provisions that I find somewhat ambiguous and am operating in a field I know nothing about. But it’s going to have huge implications for the future. So why isn’t the way to go about this case to ask the agency to issue some regulations? Then when we see their interpretation, you all will be able to argue that their interpretation exceeds the statutory delegation. And by doing that, we would have a better picture.

However, since neither the FDA nor the USPTO oversee the patent dance, it will be up to the Court to interpret these biosimilar patent dance provisions.

Read More About This Biosimilar Dispute

These articles discuss previous proceedings in Amgen v. Sandoz and explain the biosimilar patent dance issues in more detail:

If the Court follows its usual schedule, a decision will be rendered by the end of the Court’s current term in June.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP
Contact
more
less

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.